Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Issue 3 (18th January 2023)

• Record Type: Journal Article
• Authors: Wharton, Sean; Batterham, Rachel L.; Bhatta, Meena; Buscemi, Silvio; Christensen, Louise N.; Frias, Juan P.; Jódar, Esteban; Kandler, Kristian; Rigas, Georgia; Wadden, Thomas A.; Garvey, W. Timothy
• Is Part Of: Obesity. Volume 31:Issue 3(2023)
• Page Start: 703
• Page End: 715
• Publication Date: 2023-01-18
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.23673
• Languages: English
• ISSNs: 1930-7381

Abstract

Abstract: Objective: This study evaluated the effect of once‐weekly semaglutide 2.4 mg on 2‐year control of eating. Methods: In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19‐item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity. Results: In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86), mean body weight changes were −14.8% (semaglutide) and −2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 ( p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 ( p < 0.05); and for hunger and fullness at week 20 ( p < 0.001). Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 with semaglutide. At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05). Conclusions: In adults with overweight/obesity, semaglutide 2.4 mg improved short‐ and longer‐term control of eating associated with substantial weight loss. Abstract :